Posted by Michael Wonder on 03 Apr 2018
Relief for sufferers of neuroendocrine cancer after PHARMAC funding decision
1 April 2018 - Kiwis living with neuroendocrine cancer say they are relieved after PHARMAC recommended their treatment should be made available in New Zealand.
New Zealanders with the disease currently have to travel to Australia for treatment at their own expense for Peptide Receptor Radionuclide Therapy.
This week, PHARMAC's Pharmacology and Therapeutics Advisory Committee recommended the treatment should be provided for.
